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Cellular and Molecular 
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Damage in Giant Cell Arteritis, 




Giant cell arteritis (GCA) is a primary systemic vasculitis characterized by 
systemic inflammation and vascular insufficiency of large and medium blood 
vessels which may lead to end-organ damage in patients age 50 and older. Standard 
corticosteroid treatment of GCA significantly improves the intima-media thickness 
while having less influence on vascular endothelial dysfunction. GCA morbidity 
may be related to both cardiovascular complications and corticosteroid toxicity. 
Therefore, we aim to discuss 1) characteristic aspects of vascular damage, 2) several 
mechanisms that cause vascular dysfunction, intima-media ‘nodular’ thickness, 
progressive narrowing of the arterial lumen and vascular blockage in the context 
of systemic inflammation, thrombosis and of the cardiovascular complications in 
GCA and 3) new therapeutic glucocorticosteroid-sparing (GS) agents which might 
be a more productive way of avoiding the invalidating or life-threatening cardiovas-
cular complications of GCA.
Keywords: giant cell arteritis, mispositioned inflammation, vascular remodeling,  
von Willebrand factor, thrombosis, GS-saving therapeutic agents
1. Introduction
Vasculitis is a heterogenous group of conditions characterized by inflammation 
of the vessel wall resulting in narrowing or occlusion of the vessel lumen, aneurysm 
formation and impairment of downstream organ functions [1–3]. Vasculitis is clas-
sified according to the predominant size of the vessels involved into large, medium 
or small vessel vasculopathy [1–3].
Giant cell arteritis (GCA) is an autoimmune disease of the blood vessels, a 
disease where the immune system not only fails to protect but actively damages the 
blood vessels [4]. It is the most frequent primary vasculitis in adults. It manifests 
in patients mid age and older (odds 1:500 in this age group) [1]. The estimated 
annual incidence worldwide is 2.4 to 32.8 cases per 104 [3, 5]. GCA is a large-vessel 
vasculitis which has tropism for thoracic aorta and its extracranial branches [3, 6]. 
It affects mostly ethnic groups of northern European descent [7], especially female 
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gender (3:1 ratio) [7, 8], and immune response polymorphisms associated with 
HLA-DRB1*04 alleles [9]. In a genome-wide association study collected from 
over 2000 GCA patients of European ancestry [9], two independent signals in the 
human leukocyte antigen MHC HLA II class region were reported recently to be 
strongly correlated with GCA [9]. Plasminogen and prolyl 4-hydroxylase subunit 
alpha 2 (an enzyme involved in collagen synthesis) have important roles in vascular 
damage and neoangiogenesis [9] and gene variants of both proteins are related 
to high GCA risk, suggesting a role of these factors in the underlying pathologic 
mechanisms of GCA [9]. The nongenetic etiopathogenesis of GCA is also not 
completely understood [1]. The role of environmental factors (the incidence of the 
disease increases seasonally) [7], viral (herpes-infected mice develop large vessel 
arteritis [10]) and bacterial infectious agents was reported [1, 7, 10].
The arterial adventitia (the external arterial layer where the GCA inflamma-
tion starts before it spreads inward) is rich in dendritic cells (DCs) [4]. These 
cells get activated by the interaction of their own toll-like receptors (TLRs) with 
pathogen-associated molecular patterns (PAMPs) [11]. Dendritic cells are immuno-
surveillance cells which belong to the vessel wall, and, when activated, synthesize 
proinflammatory cytokines leading to activation of GCA pathogenic cascade 
[12–14]. To date and to our knowledge, no unique triggering pathogen has yet been 
singled out in GCA [1, 4].
GCA has a large spectrum of clinical manifestations [1], and many times it goes 
undiagnosed until a considerable amount of damage is done and complications 
occur [1]. People with GCA often are referred to several specialists: ophthalmolo-
gist (for partial/total visual loss), neurologist or ORL (for severe headaches and 
jaw pain), rheumatologist (polymyalgia reaction); when in fact GCA is a problem 
caused by inflammation in arteries of large and medium size [1, 6]. Ischemic 
complications of GCA and other systemic complications might be resulting in 
significant comorbidities and death [8]. If treated promptly and properly, the life 
expectancy does not change [15].
Temporal artery biopsy (TAB) is a gold standard for diagnosis of GCA [1]. TAB 
reliability might be reduced by the segmented pattern in which the lesions occur in 
the blood vessel [16, 17] and by longer time treatment (over 2 weeks) [1, 18].
Due to the fact that imaging testing might not be readily available, the use of 
biomarkers in laboratory testing for GCA is highly valuable but there are no specific 
diagnostic or prognostic blood biomarkers yet found for GCA [1]. The main criteria 
used to diagnose GCA are the elevated inflammatory markers [1] usually associated 
with for ischemic events. Acute phase reactants frequently have high blood levels: 
erythrocyte sedimentation rate (ESR) and more sensitive C-reactive protein (CRP), 
elevated platelets and white blood cell numbers, elevated blood von Willebrand 
factor (VWF) [1, 19, 20]; and in addition, GCA is associated with normocytic 
normochromic anemia [1]. Elevated serum level of the proinflammatory cytokine 
interleukin 6 (IL6) is critical in GCA pathogenesis and perhaps the most sensitive 
marker in GCA [21].
GCA is usually evaluated together with another related condition, polymyalgia 
rheumatica (PMR) [22]. PMR is not a vasculitis, but its relationship to GCA requires 
discussion because in some patients PMR evolves into GCA and 40–50% of GCA 
patients have polymyalgic symptoms [23]. In 20% of PMR patients with subacute 
presentation (proximal stiffness located in the shoulder area), abnormal blood 
work and high ESR and CRP, the disease will progress to GCA [22]. Imaging and 
pathology studies have shown subclinical arteritis may be much more common with 
PMR patients [18]. It is possible these two conditions represent two distinct pheno-
types of the same pathological entity [23].
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The standard therapy for GCA patients is glucocorticosteroid treatment [18] 
because it makes GCA symptoms better immediately, especially in ischemic com-
plications when it is lifesaving or avoids a permanent invalidity (partial/total visual 
loss) [21]. For instance, heightened vascular inflammation progressively affects 
more vessels, compromising carotid vessels and other branches from aorta, that 
supply blood to vital organs (GCA-related cerebrovascular events [24, 25] and GCA-
related myocardial infarction [26]) [8]. GCA affects the eye as well, and patients 
can have sudden and painless visual loss [27]. Because of the risk of progressive 
visual loss, GCA is an ophthalmology emergency for which the treatment is high-
dose methylprednisolone pulse therapy (1000 mg i.v. for 3 days) within 24 h of the 
onset of GCA symptoms, which works as an effective ‘emergency’ treatment option 
to prevent evolving optic (and progressively central nervous system) [28] involve-
ment [18]. If treatment is delayed more than 24 h, the blood supply to the eye can be 
cut off for enough time that restoration of vision might not occur. IV pulse therapy 
is followed with oral GS therapy [18].
In all, chronic administration of GS insures 90% of GCA patients will have 
GS-related side effects [29]. Therefore, a lot of research nowadays is focused on 
what treatment we can give instead of or in combination with GS to minimize side 
effects of GS in GCA, and in all the other types of vasculitis where we depend on 
GS for the immediate beneficial effects as well [30]. Ongoing clinical trial investiga-
tions are showing promising preliminary results. Most of the newer targets are not 
yet used in clinical practice because of toxicity, poor efficiency or because are under 
development, but nevertheless these biologics are key in deciphering the pathogenic 
mechanisms of GCA.
In this study we aim to (1) describe the characteristic aspects of vascular dam-
age; (2) discuss several known mechanisms that cause vascular disfunction in GCA; 
(3) overview new therapeutic GS-sparing agents which might be a more productive 
way of avoiding the invalidating or life-threatening cardiovascular complications 
of GCA. We focus on the current knowledge updates about the GCA pathogenic 
mechanisms subsidiary to ischemic complications of the disease and their targeted 
treatment.
2. Characteristics of vascular damage in GCA arteries
Healthy arteries have a large lumen, the arterial wall histology comprises three 
distinct layers. The adventitia is the external layer, separated from the medial layer 
by the external elastic lamina, the medial muscular layer is separated from the inter-
nal layer by the internal elastic lamina and the intima is composed of unistratifi-
cated endothelial cells (ECs) [3]. Positive temporal artery biopsy (TAB) is the gold 
standard of GCA diagnosis [31], however due to the segmented pattern in which the 
lesions occur a TAB in a segment without lesion will generate a false negative GCA 
test. The typical histopathology of GCA arteries highlights transmural granuloma-
tous inflammation. It consists of transmural mononuclear cell infiltration, mostly 
T cells, macrophages, numerous multinucleated giant cells (seen in 75% of cases), 
surrounded by low number B cells in all the layers of the artery [16]. The destruc-
tion of the internal elastic lamina, vascular smooth muscle cells (VSMCs) from the 
media to the intimal layer, and intima hyperplasia (IH) [1] are pathognomonic for 
GCA. IH protrudes in the lumen, progressively causing the occlusion of the vessel. 
Intraluminal thrombosis is reportedly seen in about 10–20% of GCA cases, prob-
ably occurring more frequently in the conditions of high shear in artery stenosis in 
GCA ischemic complications. A negative TAB does not exclude GCA [1].
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The kind of inflammation pattern the vascular wall will take depends entirely 
on the initial injury events. In GCA, the site of inflammation is restricted the blood 
vessel wall [4, 11]. Typical GCA pathological findings involve local vascular inflam-
mation, granulomatous infiltrate, and segmented lesions alternating with healthy 
segments [16]. GCA is characterized by a highly specific tropism to medium and 
large arteries of the upper extremities, neck and head in older people [1, 11, 32]. On 
the other hand, the fact that PMR and GCA have similar clinical presentation and a 
percentage of patients with GCA also have PMR suggest that these two clinical pre-
sentations might be two distinct phenotypes of the same pathological process [23].
Intriguingly, topography and histological structure dictate whether GCA lesions 
are likely to occur. GCA develops mainly in the 2nd-5th extracranial branches of 
the carotid arteries and upper extremities branches of the proximal aorta that have 
a highly visible internal elastic membrane and vasa vasorum. Temporal arteries are 
the most affected [1], and the vertebrobasilar [28] and the ophthalmic arteries can 
be affected as well [33]. Intracranial branches of the cervical arteries are small ves-
sels that are not prone to GCA as their elastic membranes are very thin to inexistent 
and lack vasa vasorum because they are nourished through diffusion not through 
vasa vasorum [34, 35].
2.1 Vasculitis initial events
Under physiological conditions, the vascular wall mainly acts as a barrier 
between circulating immune cells and surrounding tissues. Besides its role in blood 
transport, blood gas regulation and preservation of wall integrity, the arterial net-
work also has an immunosurveillance function [4]. The only immune cell known to 
be present in the healthy vascular wall is the intramural DCs, found in an immature 
state, characterized by the expression of C-C motif chemokine receptor 6 (CCR6) 
and a low density of Toll-like receptors (TLRs) [14].
Under pathological conditions, the large arteries turn into a target of autoim-
mune disease [4]. The main immunopathogenic mechanisms in the GCA arteries 
are progressing from the outside to the luminal side of the arterial wall, from the 
adventitia, where mural DCs reside, towards the intima [4].
2.1.1 The crucial role of dendritic cells in GCA pathogenesis
To date it is well known that DCs are the antigen-presenting cells (APCs)-
belonging to the vessel wall-responsible for the initial steps in GCA pathogenesis 
[14]. Arteries use their wall-embedded sentinel cells, the dendritic cells (DCs) [14], 
to intervene and generate inflammatory responses [11]. This ability of large arteries 
to control localized and systemic inflammation using indigenous cell populations 
is a critical trigger element in this primary vasculitis [11, 12, 14]. Vascular DCs are 
mostly localized at adventitia/media border [12, 14]. In the presence of unknown, 
diverse, and non-specific PAMPs, resident DCs activate and break the “immune 
privilege” [4] in GCA arteries [12], DCs initiate the pathogenic cascade [11] and 
DCs sense the danger from a distance through PAMPs interactions with their 
specific toll-ligand-receptors (TLRs) [11]. In contrast to physiological conditions, in 
GCA arteries, activated DCs at the adventitial/media border fail to leave the artery 
lesion site, meaning they don’t migrate to a lymph node, are retained in the granu-
lomatous infiltrates in the wall of the arteries [14], amplifying a mispositioned 
inflammation reaction [14].
The TLR cellular distribution in the GCA arteries is as follows: (1) immune cells: 
dendritic cells, T cells, monocytes, macrophages, and to a lower extent B cells (2) 
vascular cells: endothelial cells and vascular smooth muscle cells [11]. GCA artery 
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TLR fingerprint consist of high amounts of TLR2, TLR4 and TLR8, intermediate 
levels of the TLR1, TLR5, and TLR6 and lower or absent for TLR3 and TLR9 [11]. 
TLRs of vascular DCs are implicated in the strong tissue tropism of GCA [11].
In GCA, most severe inflammatory effects occur at the intima/media border, 
adjacent to the internal elastic lamina from the outside in, from the adventitia to the 
intima direction [14], but sometimes the inflammation is initiated in a tiny area in 
the vasa vasorum in intra-adventitial small vessels [31].
2.1.2 Recruitment, proliferation, and polarization of T cells into GCA arteries
Already activated adventitial DCs produce cytokines and chemokines (C-C 
motif chemokine ligand) CCL 19, 20, and 21 that trigger the recruitment of CD4+ 
T cell subpopulation, in proximity to vascular DCs [4, 36]. They in turn prolifer-
ate and synthesize chemokines (including CD4, CD61), creating an inflammatory 
environment [12]. Under the influence of the DCs and modulated by immune 
checkpoints [36], CD 4+ T cells subpopulation [37] differentiate into T helper 1 
(Th1) cells and T helper 17 (Th 17) cells [38]. Next, T cells polarize into two T cell 
lineages defined by the production of their marker cytokines Th1 cells start produc-
ing interferon gamma (IFNᵧ), while Th17 cells produce interleukins IL17 and IL21 
[38]. IFNv-releasing T cells axis and IL17/21 T cells axis, respectively, have different 
immunomodulatory effects [4].
IL-12 and IL 23 stimulate Th1 and Th17 responses, respectively, both of which 
are believed to be involved in promoting systemic and vascular inflammation, 
progression, and maintenance of inflammation [39, 40].
Interleukin 6 is the cytokine that controls the balance between proinflammatory 
Th1 and Th17 cells and the regulatory T cells, particularly involved in GCA patho-
genesis [4, 41]. Regulatory T cells normally ponder or inhibit the immune system 
response. The disturbance of T cell homeostasis is probably related to an imbalance 
in the amount of serum IL6 [42]. In patients with GCA, IL 6 is upregulated in the 
inflamed arteries and in circulation [5, 42]. Serum IL6 corelates with disease activ-
ity and is decreased when GCA is in remission [42]. T proinflammatory cells Th1 
and Th17 are in excess [38], while regulatory T cell numbers are inhibited by excess 
interleukin 6 (IL 6) [42].
Upon T cell activation in presence of an antiself attack [14], inhibitory checkpoints 
such as T-cell–inducible immune checkpoint programmed death-1/programmed 
death ligand-1 (PD-1/PD-L1) pathway are instrumental to minimize potential 
immunopathology [36]. PD1/PD-L1 pathway has a role in maintenance of tolerance, 
protective immunity, preventing autoimmunity disease, and protection against col-
lateral vascular damage [36]. PD-1 is expressed on activated T and DCs cells [36] and 
its coupling by its ligands PD-L1 or PD-L2 induces T cell receptor (TCR)-activation 
cascade in a Src homology region 2 domain-containing phosphatase 2 (SHP2) manner 
[36], resulting in immunosuppression. An aberrant PD-1/PD-L1 checkpoint in DCs 
(low amount of both PD1/PDL1) and T cells of GCA patients [36] is responsible for 
the observed DC-mediated hyperactivation of T cells, polarizing T cells to Th1 and 
Th17 [36]. The immunotolerance defect in regulatory T cells in GCA patients [41] 
is characterized by a stimulatory instead of inhibitory function of PD1-mediated 
immune checkpoint in GCA patients [36], followed downstream by a FOXP3 tran-
scription factor defect in the regulatory T cells locally in GCA arterial lesions [41] 
which leads to decrease in the number of FoxP3+ T regulatory cells and hyperstimula-
tion of proinflammatory T cells. In addition, the regulatory T cell population can be 
influenced with an IL6 receptor antagonist [41] which stresses the necessity of IL6 in 
these processes. Importantly, IL17 is controlled rapidly by glucocorticoids [4]. IFNỿ is 
resistant to corticoids, also to aspirin and NOTCH inhibitors [4, 43].
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2.1.3 Monocytes differentiation/macrophages role in GCA-related vascular damage
Under an increased level of interferon-gamma (IFNỿ) produced by CD+4 T 
cells, monocytes and macrophages are recruited in the arterial wall [44]. IFNv 
primarily targets macrophages leading to their fusion together into giant cells (GC) 
[4, 44]. IFNv concentration was found to be elevated in arterial tissue from GCA 
patients with ischemic disturbances, including visual loss [44]. In addition, they 
reported patients with PMR and fever had elevated IL2 production [44].
Using ex vivo cultures of temporal artery biopsies, Cid et al., 2006 demonstrated 
that the role of IFNỿ is to induce the production of C-C motif chemokine ligand 
2 (CCL2) (ligand of CCR2 receptor) by VSMCs [45, 46]. CCR2, the correspond-
ing receptor, is also expressed by monocytes, binding of CCR2 on monocytes 
leads to the recruitment of monocytes and their differentiation inside all layers 
of the arterial wall [46]. INFỿ induces the production of C-X-C motif chemo-
kine ligand (CXCL9, 10, 11) by VSMCs [46], linked to the recruitment of cells 
expressing CXCR3 which is expressed by Th1 cells and CD8+ cells [4]. This will 
initiate a positive feedback loop since T cells are being activated and produce more 
IFNỿ [4, 46, 47].
Macrophages have different functions depending on which vascular layer 
they are going to be trapped in (1) adventitial CD 68+ TGF β1+ macrophages 
produce proinflammatory cytokines IL1β and IL 6 [4, 11, 48]; (2) intimal-media 
junction macrophages secrete metalloproteinases to clear cellular debris. They 
are also responsible for unintended, pathological elastic membranes digestion; 
(3) macrophages in the intima layer have roles in cellular outgrowth [49]. Intima-
located macrophages led to production platelet-derived growth factor (PDGF) 
[50] which is needed for dedifferentiation, proliferation and migration of VSMCs 
[50, 51] and vascular endothelial growth factor (VEGF) which is needed for 
 neoangiogenesis [52].
IL1β and IL 6 levels are influenced by GS in GCA [43], in contrast, IL12 is mostly 
resistant to GS therapy [4, 18]. The lack of reaction to GS suggests a need for better 
therapeutic strategies to interfere with these pathologic cascades.
Monocytes and macrophages accumulate in high numbers generating granulo-
matous inflammation of large and medium arteries and, under stimulatory influ-
ence of INFv, they form giant cells (GC) by fusing together [4, 5].
In physiological conditions, GC are the body defense response against a foreign 
body or a kind of irritant, for instance, a splinter in the finger, the body will produce 
GCs to break up this irritant and remove it. In the case of GCA, ‘the foreign body’ is 
not known. It has been stated by some authors that it might be the arteriosclerotic 
plaque [53]. Macrophage multinucleated giant cells in pathological conditions of 
GCA are a unique cell population that produce different mediators leading to the 
destruction and faulty reconstruction of the arterial wall [4, 54].
3. Vascular remodeling of healthy arteries to GCA arteries
Regarding the GCA pathophysiology, studies have observed many interchange-
able features dictated by the ‘confused’ immune system and by the cellular popula-
tions of the vascular wall itself mediated by blood factors. Upon the destructive 
actions of GCs, the vessel initiates a faulty PDGF- [50] and VEGF- [55] dependent 
maladaptive reparatory mechanism [55].
GCs’ proteases digest the vascular wall at the level of the internal elastic lamina 
[54, 56, 57]. For instance, media-intima junction GCs are producing metallopro-
teinases (MMP-9 and MMP2) [57] as was demonstrated recently [54, 57], and also 
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other mediators. VEGF [55] is linked to neoangiogenesis and the recruitment of 
proinflammatory T cells via Notch/Jagged 1 dependent pathway [4, 5], reactive 
oxygen species (ROS) [54], and the other inflammatory mediators with proteolytic 
activity that cause breakage of the internal elastic lamina. The vascular response is 
a result of the two-way interaction between the hyperactive immune cells and the 
activated vascular cells. These processes lead to: (1) release of additional growth 
factors; (2) release of vWF from ECs Weibel-Palade bodies [19, 58–61]; (3) release 
of macrophage factors [13, 44, 48]; (4) media thickening in response to the immune 
insult [50] and deposition of extracellular matrix proteins (i.e. collagen); (5) intima 
myofibrotic hyperplasia (IH) [50]; (6) release of angiogenic factors in the vasa 
vasorum [62]; and finally, (7) upregulation of the proteinases [54] and downregu-
lation of their inhibitors which causes the intima elastic membrane to tear [54], 
destroying locally the vessel wall.
Most importantly, the increased production of such mediators as PDGF [50, 51] 
and endothelin-1 [63, 64], initiates a faulty vascular repair process, leading to the 
activation, dedifferentiation, proliferation, and migration of the VSMCs from 
the arterial media to the intima. This leads to myofibrous intimal hyperplasia and 
“nodular” media thickening with granulomatous giant multinucleated cells infiltra-
tion, and neoangiogenic vasa vasorum [44, 62] characteristic to GCA pathology 
[51]. Typically, VSMCs turn from a contractile cell into a dedifferentiated, secre-
tory, and migratory cell [5, 65]. Activated and injured vascular smooth muscle cells 
(VSMCs) produce growth factors (including PDGFs [55], TGF-β and ET-1 [63, 64]) 
that promote further myofibroblast dedifferentiation, proliferation and migration 
[4]. Reversely, pharmacologic blockage of the PDGF receptor or blockage ET-1 
receptors [64] results in reduced IH in cultured GCA arteries [51, 64].
In all, hyperplastic cell outgrowth in the lumen of medium sized artery through 
autoimmune vascular remodeling progressively narrows the lumen, resulting in 
vascular stenosis and ischemia in the distal organs these vessels normally irrigate. 
The eye and the brain are at highest risk. The invalidating or life-threating conse-
quences are severe, possibly visual loss or even stroke. Patients with GCA who have 
ocular ischemic complications have higher blood concentrations of ET-1 and other 
EC biomarkers, highlighting these biomarker potential role in thromboembolic 
vascular disturbances [63, 64].
3.1  The crosstalk between immune cells/vascular cells, faulty vascular repair 
and thrombosis in primary vasculitis
More and more evidence suggests the presence of crosstalk between misposi-
tioned vascular inflammation [4] and thrombosis [5, 61, 66]. In the past the under-
lying molecular mechanisms of vasculitis have been overlooked, but more recently, 
it has become increasingly evident that inflammatory diseases of the blood vessels 
are associated with arterial [25, 67] and venous thrombosis [66]. In GCA, certain 
risk factors will seriously increase the likeliness of thrombotic events, including, but 
not limited to systemic inflammation, localized vascular inflammation, endothelial 
dysfunction and treatment-related complications [5, 68]. The higher risk of throm-
bosis during active disease underlines the role of inflammation in thrombogenesis 
[61, 68]. Furthermore, GCA patients have a greater risk of thromboembolic com-
plications due to the advanced age, and to the other risk factors that they concomi-
tantly have, such as hypertension, smoking, hypercholesterolemia, previous arterial 
thrombotic events, family history of thrombosis, and the presence of additional 
cardiovascular risk factors [25, 28, 61, 68]. This may contribute to the choice of 
administrating antithrombotic therapy: low dose aspirin 75–250 milligram per day 
prevents cerebrovascular events and ocular symptoms [69]. Antiplatelet therapy 
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influences arterial disease events [69], while anticoagulants and immunosuppres-
sive medication have a debatable effect [21, 70].
3.1.1 Immune cells response in vasculitis
A growing body of evidence supports the above-mentioned ‘outside-in’ hypoth-
esis that vascular inflammation is initiated and perpetuated in the adventitia in 
GCA and contributes progressively to medial and intimal remodeling [14]. Once the 
immune barrier is broken [12], the vessel expresses cell surface adhesion molecules 
in the vasa vasorum [55] and inflammatory mediators [5]. In result, the monocytes 
migrate towards the intima of the blood vessels [53]. Th1 and Th17 T-cells patho-
genic pathways promote the production of IFN-ỿ and, respectively IL-17 [38, 38]. 
Th17 differentiation via its effector IL17 pathways induce chronic inflammation 
[71]. B cell differentiation contribute less to the formation of granulomatous struc-
tures [4, 5]. Cytokines like TNF alpha, interleukins IL1β and IL6 are promoting not 
only systemic signs in primary vasculitis (fever, malaise, weight loss, fatigue) but 
they also favor a prothromboembolic state [61, 67]. GCA complications comprise 
arterial [67] and, although less frequent, venous involvement, both DVT and PE 
[66]. In mouse models of DVT, it has been demonstrated high IL 6 during throm-
bogenesis [72], while inhibition of IL6 reduces expression of CCL2 which leads to 
a low recruitment of monocytes at the site of thrombosis of the vessel wall and the 
post-thrombotic syndrome [72]. IL6 is triggering an amplification and recruitment 
of monocytes which is in relation to the ability to express in excess cell adhesion 
molecules in vasa vasorum [4]. One puzzling observation from published data is 
that IL 6 pleiotropic effects on immune and vascular cells assert disease activity in 
GCA, however, when IL6 expression in the temporal artery is low, the IL6-induced 
angiogenic response is decreased without a protection mechanism against ischemic 
events in GCA patient [42]. Acute phase proteins are elevated: serum amyloid A 
(SAA), CRP, ESR, WBC count and platelet count [1]. GCA patients having ocular 
complications have significantly decreased level of SAA, CRP and ESR [27] as well 
as high VCAM1 levels [73]. GCA patients during relapses had significantly higher 
levels of SAA, CRP, ESR and WBC counts [73, 74].
Hyperactivated T cells and macrophages organize the granulomatous lesions 
in the vessel wall [44], destroy the media layer, the inflamed artery initiates an 
abnormal vascular repair program [11], inducing ischemic organ damage through 
intimal hyperplasia and luminal occlusion changes [5, 36]. Elevated IFNv was 
demonstrated to be correlated with neoangiogenesis [4, 62], and IH [46], two 
critical processes in vascular remodeling in GCA artery. Persistance of IFNv cor-
relates with chronical arterial inflammatory disease [4]. Clinical variations in GCA 
are correlated with local expression of cytokine mRNA (elevated IL1β, IL6, TGF, 
IL2, INFỿ, IL17, 13). Heterogeneity of immune response and targeting of the arterial 
tissue in a TLR-specific manner explain the diverse clinical manifestations inside 
GCA spectrum of diseases [4, 11].
3.1.2 Vascular wall response to vasculitis
In GCA pathogenesis it is thought that the vascular wall response has the same 
impact as the immune cell response [4].
3.1.2.1 Arterial luminal vs. vasa vasorum endothelial cells response in GCA
Vascular endothelial dysfunction was previously reported in GCA [53]. It is 
associated with elevated blood levels of proinflammatory endothelial factors that 
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have important roles in the pathogenesis of GCA: endothelin 1 (ET-1, 64], and cell 
adhesion molecules [19, 64, 75], and von Willebrand factor (VWF) [19, 20, 53, 59]. 
The presence of the proinflammatory and procoagulant factors at GCA lesions sites 
is indicative of the extensive crosstalk between immune system and vascular cells 
[61]. The contribution of the blood vessel wall to the GCA pathogenesis is stressed 
by the fact that symmetrical, collateral vessels are much more likely to be affected 
(implicating GCA strong tissue tropism [4] in contrast to, for instance, atheroscle-
rotic diffuse display which also manifests in this age group [53]) as demonstrated in 
these patients by PET scans/CT angiography imaging [17, 73].
Thrombin, the main protease in the coagulation cascade, also has numerous 
effects on the endothelium, i.e. thrombin-induced expression of chemokines 
that trigger binding of platelets and monocytes to the endothelial surface [76] 
and increased permeability across endothelium [77]. By these and many other 
mechanisms [78], thrombin is coupling coagulation and inflammation [61, 78, 79]. 
The stimulatory effects of thrombin on ECs and platelets occur mainly through 
activation of the protease-activated receptors (PARs) [79]. PARs are seven-trans-
membrane G protein coupled signaling proteins [80]. PAR1 is the prototype for a 
family of four related receptors [79]. PAR1 is the key mediator of thrombin’s effect 
on human ECS [79]. Thrombin activates PAR1 receptors which couple to Gαq/11 
and Gα12/13 that upregulate the vWF and P-selectin secretion from the ECs storage 
granules named Weibel Palade bodies (WPBs) [79, 81, 82]. Soluble P-selectin is 
an adhesive molecule also stored in WPBs [81]. Relevantly, P-selectin secreted by 
luminal endothelium of the carotid artery in a murine vascular damage model was 
reported to be involved in monocyte trafficking and neointima formation [65].
One of the mechanisms that may cause endothelial dysfunction in primary 
vasculitis is the excess of proinflammatory cytokines that are depressing endothe-
lial function [31]. Also, the inflammatory microenvironment is directly leading 
t0 endothelial cell toxicity. In addition, healthy and pathologically damaged cells 
are intercommunicating and interconnecting, for instance monocytes and GC 
interactions close to the vessel wall trigger endothelial damage. Another role of the 
endothelium in inflammation is in leukocyte trafficking (P-selectin, E-selectins 
expression) [55] and the expression of cell adhesion molecules in the vasa vaso-
rum [55]. Transcript levels for markers of endothelial activation: VWF, ICAM1, 
VCAM1, CD31, VE-cadherin (and of myofibroblasts smooth muscle cells actin 
(SMA)) measured by RT-PCR in the tissues in a GCA mouse model [36] were found 
to be elevated by up to fourfold when PD-1 was blocked with anti-PD-1 Ab when 
compared with control IgG or vehicle-treated [36] immune checkpoint inhibition 
led to intimal hyperplasia, angiogenesis and nodular thickening of the media. 
Inflammation-induced effects caused by the endothelium in systemic inflammation 
disease include but are not limited to: (1) increased expression of procoagulant 
factors: VWF, plasminogen activator inhibitor 1 (PAI1), platelets activated factor 
(PAF), vascular cell adhesion molecule 1 (VCAM1), intercellular adhesion molecule 
(ICAM1) and tissue factor (TF) and (2) and inhibition of anticoagulation pathways 
and fibrinolysis activity: endothelial protein C receptor (EPCR), tissue plasmino-
gen activator (tPA), thrombomodulin (TM), prostaglandin I 2 (PGI2), that are 
causing thrombotic tendency [61, 83]. In patients with visual disturbances there 
were reported high VCAM1 levels compared with GCA patients that did not have 
visual disturbances [73]. VCAM1 was also significantly correlated with large vessel 
envolvement [73].
Weibel-Palade bodies (WPBs) are the secretory granules of vascular ECs [81]. 
The main resident of WPBs is vWF [81, 84]. vWF is pro-inflammatory and pro-
thrombotic agent which plays a central role in morbidity and mortality associated 
with systemic inflammation and cardiovascular disease. The fact that elevated vWF 
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in the circulation is a marker of inflammation-induced activation of ECs is well 
established [82, 85], but why do activated endothelial cell release von Willebrand 
factor in the context of the pro-inflammatory microenvironment in vasculitis, in 
particular in GCA, by which mechanism, is not completely understood; it was sug-
gested it is part of the reparatory process. When an immune checkpoint is inhibited, 
endothelial cells are bigger in size and increased VWF expression and secretion was 
reported [36], indicative of endothelial cell maladaptive reaction. Moreover, VEGF 
derived from macrophages and the other immune cells have a stimulatory influence 
on Weibel-Palade bodies’ secretion of VWF and angiopoetin-2 [86] involved in 
neointima formation. Intriguingly, it was reported that PDGF released by vascular 
dendritic cells [55] -on top of the above-described proinflammatory features- regu-
lates vWF gene promoter.
vWF is an important molecular link coupling thrombosis and inflammation. It 
was found to contribute to systemic and vascular inflammatory manifestations of 
GCA. VWF levels are elevated in GCA patients circulation up to three-folds [19]. 
Highest vWF values are recorded at the onset of the disease [19], high blood VWF 
levels are persistent throughout the active disease period and remain elevated in 
some patients a long time after corticosteroid treatment [19, 59]. According to 
Persellin et al. elevated blood vWF values are not due to impairment of vWF for-
mation or storage but to increased ECs secretion of normal von Willebrand factor, 
as shown by electrophoretic analysis of high molecular weight vWF polymers pat-
tern [20]. High active VWF levels reflect vascular distress that predicts the course 
of the disease towards vasoocclusive problems [20]. Intraluminal thromboses 
were seen in 10% in TAB+ GCA, but in fact, the rate might be higher and hidden 
by the concomitant hyperplastic reaction in the intima. Several studies proposed 
VWF could be a parameter to monitor treatment or a parameter for diagnosis 
when the acute phase reactants (ESR) are normal in treated GCA patients. The 
fact that elevation of VWF is persistent throughout the steroid treatment sug-
gests that GS treatment has little effect on the underlying endothelial disease. 
A significant percentage of patients receiving steroid treatment are developing 
irreversible vascular occlusive complications episodes (%) even after receiving GS 
treatment [67].
Several studies investigated the role of vWF in the formation of the hyperplasic 
intima (IH) [58, 60]. In one study, matching TABs and matching blood collec-
tion was done for VWF measurement. Increased vWF deposition in hyperplastic 
neointima mirrored high plasma vWF levels [19]. These data and other published 
data- that increased levels of vWF are associated with hyperplasia in grafts [87], 
and no occurrence of atherosclerotic plaques in vWF deficient pigs [88] -suggests 
a role for vWF in vascular remodeling and faulty vacular repair [60, 75]. Indeed, in 
a recent study by Lagrange et al. [58] it was found that vWF/LRP4/integrin α vβ3 
axis stimulates proliferation of VSMCs: (1) vWF binds through its A2 domain to 
the VSMCs LRP4 receptor; (2) crosstalk LRP4 receptor-integrin α vβ3; (3) integrin 
α vβ3 activates Src signaling leading to vWF-dependent VSMCs proliferation [58]. 
Relevant to the aim of this review, their new findings provide new insights into the 
pathogenic mechanisms that drive pathological hyperplasia of the GCA arterial 
vessel wall. Moreover, the vWF/LRP4/integrin α vβ3 axis may represent a novel 
therapeutic target to inhibit VSMC proliferation, and, at least partially, prevent the 
maladaptive reparatory process in GCA [58].
At high shear-rates-which is the case in our pathogenetic context in the artery 
stenosis provoked by vascular remodeling in select ischemic complications of GCA, 
the inactive, globular circulating vWF unfolds into a highly active HMW elongated 
conformation. The active, elongated vWF can bind platelets via its repetitive A1 
domain forming’beads on a string’ conformations the incipient steps of thrombus 
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formation [82]. von Willebrand factor, then, has a two-way pathogenic mechanism 
to actively participate in GCA artery occlusion, on one hand, because at the site 
of the autoimmune vascular lesion, VWF, released from systemic inflammation 
thrombin-activated vascular ECs, initiates platelet adhesion, and changes the 
thrombotic propensity [19, 59], and on the other hand, amplifies maladaptive 
vascular response via vWF/integrin axis [58], based on these published data it 
is highly probably that the rate of intraluminal thrombotic events is higher than 
expected and the rate of TIA in GCA patients is also probably to be higher. It is 
worth mentioning here that episodes of transient visual loss precede permanent 
visual loss in 44% of cases [27]. To conclude, these two roles of vWF in GCA arter-
ies are most likely associated with poor outcome of cerebral, coronary, or ocular 
ischemic complications of GCA disease [67]; leading in some people to type 2 
GCA-related myocardial infarction [25, 26]. The highest VWF levels were recorded 
in GCA patients with positive temporal arteries biopsy when associating ocular 
symptoms [20], further studies are needed for vWF role in the ischemic complica-
tions of GCA. Reversely, in PMR, they reported lower levels of VWF than in GCA, 
which might be indicative of a lower degree of endothelial dysfunction, in PMR it 
correlates with the severity of the clinical signs, “more fuel on the fire” in the course 
of the disease [20]. For all these purposes, accurate criteria for active GCA disease 
are needed.
GCA relapsing cases or cases unresponsive to corticosteroid therapy that also 
have high blood VWF levels, high ESR, eye symptoms, would be candidates for 
testing new prospective therapeutics that either block vWF release from ECs 
activated by inflammatory cytokines in GCA [19] or block the mitogenic effect of 
vWF on IH [58].
3.1.2.2 Vasa vasorum ECs response to vasculitis
In response to activated vascular DCs in the adventitial layer, the invasion of 
multiple types of immune cells is currently thought to occur through the vasa 
vasorum endothelium [4]. The question to ask is why and how endothelial cells of 
the tiny adventitial vessels allow the immune cells to break into the vascular wall 
of the GCA arteries. The role of vasa vasorum ECs is major in GCA pathogenesis 
though the molecular details are still cryptic. In PMR and GCA as well, adventitial 
macrophages stimulated by DCs produce IL6 and IL1 which are detected from the 
early stages, when temporal artery is histologically apparent normal and the INFỿ 
expressing T cells are still absent from the vascular wall [11, 13]. At these early 
stages it is expected that vasa vasorum ECs are activated, express selectins and 
have a role in increasing wall permeability. In the same time, new vasa vasorum are 
formed, not only in the adventitia, but across all layers of arterial wall. Their role is 
to transport the invading immune cells.
3.1.3 Platelets response to vascular inflammation
Platelets are activated by the following activated EC factors: (1) increased 
thromboxane A2; (2) increased von Willebrand factor and (3) decreased prosta-
glandin I2 [83]. Platelets are activated by the pro-inflammatory cytokines expressed 
by ECs and immune cells, by PAF, and by thrombin [83]. When activated, platelets 
secrete P-selectin and directly interact with endothelial cells [83]. Activated plate-
lets interact with monocytes and neutrophils through the NF-KB mediated pathway 
[4, 83]. Activated platelets release pro-inflammatory cytokines or chemokines (like 




3.2  Thromboembolic complications in GCA patients-clinical features and 
pathophysiological data subsidiary to vascular dysfunction
3.2.1 Arterial thrombotic complications in GCA
Most common clinical features in GCA patients are the ischemic symptoms: 
headache, jaw claudication and visual symptoms. If not promptly treated, GCA can 
lead to systemic complications: aortic aneurysm and rupture, and to ischemic com-
plications of GCA: myocardial infarction, stroke, and blindness. Patients with GCA 
are experiencing these syndromes due the progressive vessel stenosis/occlusion 
of the affected arteries, secondary to vascular damage and IH. Several pathogenic 
mechanisms could explain the increased risk of thromboembolic complications in 
patients with GCA, including immune and vascular cell aging [89], stasis, endo-
thelial dysfunction, hypercoagulability, and decreased fibrinolysis, the features of 
inflammatory-derived thrombosis.
3.2.1.1  Cranial symptoms-involvement of intra carotid artery and vertebrobasilar 
branches
Cranial symptoms are classically associated with GCA: new onset headaches, the 
most common initial symptom, typical in temporal area but can be diffuse/nonspe-
cific, persistent throughout the day, partly responsive to analgesics; scalp tender-
ness seen in 50% of patients; usually noticed while brushing hair; temporal artery 
abnormalities pulse; jaw claudication is seen in 50% of patients, the most specific 
symptom of arteritis, is a mandibular pain brought on by speech and mastication, 
relieved when stopping the activities, highly suggestive of GCA, strongly associ-
ated with positive TAB. In rare cases, muscles of the tongue and swallowing may be 
affected.
3.2.1.2 Stroke in GCA
Most strokes in the investigated GCA patients were found in the vertebrobasilar 
and internal carotid artery territory [33, 90]. The reported rate of stroke/transient 
ischemic attack (TIA) is approximately 5–20% [25, 33]. The underlying mechanism 
of cerebrovascular ischemia is related to the vascular dysfunction that is character-
istic of GCA. More recent GCA studies [28, 33, 67] reported a 2.8% -7% incidence 
of ischemic stroke. As mentioned on previous section, a lot of inflammatory cells 
collect around internal elastic lamina but intracranial arteries lack an internal 
elastic lamina that being one of the reasons stroke is not seen as a severe manifesta-
tion of GCA in that territory.
In a cohort study evaluating the thrombotic risk in GCA patients vs. control it 
was found an increased risk of cerebrovascular accidents like in the other studies, 
and also peripheric arteritis and myocardial infarction [25]. The incidence rate 
ratio for CV events was 1.68 [25]. There is a significantly increased risk of throm-
boembolic disease in GCA during active disease; the risk for thrombotic events was 
reportedly the highest in the first month from the onset of the disease hazard ratio 
4.92 (95% CI 2.59–9.34. The risk for CV risk was much decreased at a follow-up 
(hazard ratio of 1.70) (95% CI 1.51–1.91) [25]. Although patients with GCA have 
an increased risk of cerebrovascular accidents, long-term survival study concluded 
that GCA patients’ mortality is not higher than in the general population if treated 
properly [34].
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3.2.1.3 Visual symptoms-internal carotid artery branches involvement
Blindness is the most severe thromboembolic event experienced by 15–20% of 
GCA patients, usually at onset [6, 27]. It is rarely reversible. Visual loss is abrupt 
and painless and the most feared consequence of GCA by the clinicians. GCA is an 
ophthalmology emergency which requires ‘emergency’ IV pulse therapy with high 
dose prednisolone followed by oral therapy to prevent progression in the affected 
eye and extension to the contralateral eye [21].
Transient monocular visual loss (TMVL) or amaurosis fugax means a person 
cannot see through one or both eyes, a symptom of poor blood supply to the eye(s). 
TMVL is seen in 10–15% of patients. If left untreated 50% of cases are rapidly pro-
gressing to permanent visual loss (VL). Unilateral VL is a strong risk factor for VL 
in the contralateral eye which can occur in more than 50% of cases within 2 weeks if 
left untreated [27].
VL is usually due to arteritic anterior ischemic optic neuropathy: occlusive arte-
ritis of the posterior ciliary branches of the ophthalmic artery which are the main 
arterial supply of the optic nerve [91]; it accounts for 85% of all VL cases in GCA 
[27, 91]. VL can also be due to central retinal artery occlusion or posterior ischemic 
optic neuropathy [27, 33, 91]. Other ocular symptoms in GCA might be ophthalmo-
plegia and diplopia from ischemia of the extraocular muscles and blurry vision [27].
Intriguingly, one of the acute phase reactants, an innate immunity pattern recogni-
tion receptor, pentraxin 3(PTX3) accumulates at the site of active vascular remodeling, 
more so in GCA patients with recent ocular ischemic events ischemia [52], indicative 
of thrombo-inflammation manifestations in GCA vessels that supply the eye, as shown 
by immunohistochemistry and measurement of plasma levels of PTX3 [52].
3.2.1.4 Extracranial/large vessel involvement
Extracranial/large vessel involvement refers to involvement of aorta and its major 
branch vessels. About 25–30% of GCA cases have clinically evident large vessel 
involvement [90] but PET scans and CT angiography have demonstrated that sub-
clinical large vessel involvement is present in a significant percentage of cases [90]. 
The GCA vasculopathy may evolve to aneurysm formation and vascular rupture of 
aorta and stenosis/occlusion of its branch vessels [68]. Clinically, these patients may 
present extremity claudication, absent peripheral pulses, abdominal pain, masked 
HTA, dizziness depending on affected vessels. Because of risk of vascular stenosis, it 
is needed an evaluation of the blood supply. If decreased blood supply is found, the 
question is if this is part of GCA occlusive complications or related to artherosclerosis 
which is almost universal in people in this age group that develop GCA or both. Leg 
vessels are less involved in GCA than the arm, the neck, the brain, or the eye vessels, 
but vascular complications can occur in the leg too, just less frequently. Blood pres-
sure and pulses discrepancies of 15-20 mg between left and right extremities might 
raises question of large vessel arteritis involvement and might hide hypertension.
3.2.2 Venous thrombotic complications in GCA
In a cohort study of circa one thousand GCA patients, an increased risk of 
venous thromboembolism was observed (both DVT and pulmonary embolism), 
during the early active, uncontrolled phase of the disease [66].




4.  Vascular remodeling is the ‘unmet need’ in GCA treatment-standard 
therapy and future perspectives
4.1 Glucocorticosteroids treatment-advantages and disadvantages
The glucocorticosteroids (GS) remain the drug of choice for the GCA treat-
ment. In presence of the characteristic clinical signs, GCA is diagnosed by using the 
Westergren method, high erythrocyte precipitate is indicative of this inflammatory 
condition and the indication is to start the GS therapy without delay and followed up 
with a biopsy of the temporal artery [29]. GS treatment is started with about 1 mg/
kg/day prednisone and then is tapered at 3, 6, 9 and 12 months-a long taper with 
intend to withdraw GS around 12–24 months [29]. GCA disease, if treated properly, 
has an excellent prognosis, but it is difficult for most people to be tapered off pred-
nisone entirely. Most GCA patients must take low dose prednisone daily for months 
and years. GCA patients are elderly people, a prednisone hit on top of a frail constitu-
tion leads to higher disease toll compared to if the disease would occur earlier in life.
About 50% patient relapse after a mean follow up of 7 months at a mean predni-
sone dose of 4 mg/day [29]. Furthermore, GS are generating side effects, about 90% 
of patients receiving prednisone for GCA will have at least one GCA-related side 
effect after 1 year [29].
The question to ask is what we can add or substitute for GS to get tide control 
of the disease and address the unmet need of vascular luminal changes. GS are eas-
ing the symptoms quickly, by blocking inflammatory responses, probably correlated 
with the rapid decrease in the serum IL 6 and blockage of activation, proliferation, 
and polarization of the T cells, in particular of Th17 cells. Therefore, GS are still 
the best available treatment for the induction and remission of GCA, but, unfor-
tunately, they fail to resorb the vessel wall infiltrates or to attenuate the underlying 
vascular dysfunction pathogenic mechanisms. It is not well known how GS inter-
vene on systemic inflammation’s vascular component in GCA, but for instance Cid 
et al. 2000 reported that GS treatment was not sufficient to completely abrogate 
the expression of adhesion molecules, [55] in their patients, indicating a persistent 
exposure of ECs and VSMCs cells to a remaining inflammatory microenvironment 
despite the rapid symptomatic improvement achieved at follow-up after GS treat-
ment. Moreover, GS have no effect on the restoration of regulatory T cells, and mild 
effect on TH1 polarization [21, 29]. Another interesting study on 40 patients with 
TAB+ GCA treated with prednisone, in which they had a randomization for follow-
up TABs at 3, 6,9 and 12 months, has shown that in 50% of cases, positive TAB histo-
pathologic signs were still present after one year of GS treatment, showing GS have 
little to zero effect on vascular remodeling [21, 92, 93]. Vascular remodeling remains 
the unmet need of current GCA therapy [43, 93]. Therefore, it is very important to 
develop new strategies to spare GS in GCA. Some of the drugs proposed in the past 
are toxic or ineffective [5].
The other drug that is recommended for almost all GCA patients is low dose 
aspirin (85 mg a day) because it decreases the risk of developing subsequential 
visual loss or cerebrovascular events in giant cell arteritis [69], and it addresses any 
thrombogenic tendency in blood vessels supplying the eye and the CNS. Some more 
recent studies challenge the benefit of using aspirin in GCA treatment [5]. The use 
of otherconventional anticoagulant therapy for the thromboembolic complications 
of GCA remains controversial and is not recommended [5, 70].
Up to more recent date, the only GS-saving agent was methotrexate [5]. It was 
demonstrated in a metanalysis gathering phase III randomized blind controlled 
trials on 161 patients that methotrexate decreases the risk of GCA relapses and is 
able of GS-saving effect [43].
15
Cellular and Molecular Characteristics of Vascular Damage in Giant Cell Arteritis, the ‘Unmet…
DOI: http://dx.doi.org/10.5772/intechopen.97933
4.2 Experimental models of GCA
In most to-date published studies, the biochemical assays were conducted on 
cultured human arteries collected by TAB from GCA patients compared with 
healthy cultured arterial cells, according to protocol from healthy subjects unrelated 
to GCA and on peripheral blood collected from GCA patients.
Several murine models of large vessel vasculitis are currently available [5, 43]. 
Some murine models are KO for genes which encode proteins that have crucial roles 
in GCA pathogenesis. IL1 rn−/− mice are lacking the gene encoding for the IL 1 
receptor antagonist and it was found that these mice develop T-cell dependent vas-
culitis [5, 43]. Others used herpes virus-infected mouse models of vasculitis [10]. 
Another model involved microsurgery and physical contact of the murine aorta 
with an elastase to destroy the vascular wall and mice developed aortitis [5, 43].
The most interesting systemic murine model developed by Weyand group 
[4] uses implant of human temporal artery (allowing dissection of specific GCA 
pathogenetic mechanisms) or infusion of human peripheral blood monocytes from 
GCA patients in severely immunodeficient mice [38]. The model of subcutane-
ous engraftment of human TAB+ GCA arteries in severely immunodeficient mice 
opened the possibility to test new biologics therapy effects on immune cells and its 
afferent GCA artery, both cells and GCA artery originating from the specific patient 
in the murine model of GCA, maybe allowing in future studies collection of predic-
tive data on how a specific GCA patient would react to the administrated drug of 
choice [4].
4.3 GS-sparing agents for GCA treatment
4.3.1 Tocilizumab and GiACTA study
One of the most important therapeutic targets for the treatment of GCA disease 
is related to IL6.
Tocilizumab is a monoclonal antibody targeted against IL6 receptor α [94]. IL6 
is the cytokine that controls the balance between regulatory T cells, Th17 and Th1 
which is particularly involved in GCA pathogenesis. Collectively, IL6 published 
data leaded to the breakthrough Giant cell Arteritis Actemra (GiACTA) study was 
published in 2017 by Stone et al. [94]. GiACTA is a global, randomized, double 
blind, double placebo-controlled Phase III trial evaluating efficacy and safety of 
tocilizumab in active GCA in which there were compared 4 groups: in two groups 
people where receiving IL6 receptor antagonist tocilizumab every week or every 
other week in association with prednisone over 6 months or 1 year; in the two pla-
cebo groups patients were receiving prednisone either 6 months or 1 year [94]. The 
primary outcome measurement at one year was the sustained remission (56% of the 
patients in weekly tocilizumab group and 53% in those receiving every other week 
tocilizumab group compared to only 14% in the short-course prednisone without 
tocilizumab group, of a total of 251 patients) [95]. GiACTA results demonstrates 
the superiority of tocilizumab to placebo non-dependent on the duration of predni-
sone, sustained remission, excluding CRP concentration normalization [94].
GiACTA lead to the FDA approval of tocilizumab in 2017 as first and only 
specific therapy to treat GCA in the USA and Europe [30, 95], in combination with 
protocol-defined dose of GS. Tocilizumab successful clinical trials indicate that 
blockage of IL-6-dependent inflammatory pathways strongly inhibits systemic 
inflammation as well as PMR and ocular syndrome in GCA patients [30, 95]. 
Tocilizumab prescription is particularly useful in corticodependance and severe 
adverse reactions to GS (osteoporosis, diabetics, HTA) [30, 95].
Giant-Cell Arteritis
16
There were a few reports of what happens after tocilizumab withdrawal. In an 
effort to optimize the tocilizumab treatment duration, a multicenter prospective 
open label study investigated the risk of relapse associated with tocilizumab discon-
tinuation after new GCA patients received 4 infusions of tocilizumab at weeks 0, 
4, 8 and 12 wks [5, 43]. They observed that this treatment can be very effective, but 
after tocilizumab termination, at least in some patients (25%), it was seen relapse 
revival [43]. Same, in a long-term follow-up of the GiACTA study confirmed on 
larger number of patients, in which the treatment was stopped at one year, the 
relapse revival decrease was seen and it was more comparable between groups after 
two years follow-up [43, 93]. Importantly, there is no proof of tocilizumab efficacy 
on vascular remodeling. One of the molecular effects of IL-6 blockade was reported 
by Terrades-Garcia et al. who investigated the molecular effects of tocilizumab; 
for this study temporal arteries from 13 GCA patients and 8 controls were cultured 
with or without tocilizumab. After 5 days of culture, tocilizumab selectively 
induced a decrease in CXC 13 chemokine mRNA expression in cultured arteries, 
and they concluded disruption of B cell homeostasis may partially account for the 
therapeutic effects of tocilizumab (ACR meeting 2016), with no significant changes 
in other chemokines [5]. Further studies are needed to identify predictive factors of 
relapses.
4.3.2 Therapeutical targets-updates and controversies
METOGia is a currently conducted, randomized controlled clinical study 
comparing administration tocilizumab for one year with one-year treatment of 
methotrexate in association with protocol-controlled prednisone [43].
A new IL1R antagonist (anakinra) effects in GCA treatment is currently under 
clinical trial, with promising perspective [43].
Activated T cells could be moderated by inference at immunoinhibitory check-
points [36]. A potential drug intervention is to control excessive TH cell activation 
and invasion along arterial wall by using abatacerpt. Abatacept is a recombinant 
fusion protein made from fragment of human Ig1 fused to a domain of cytotoxic 
T-lymphocyte-associated antigen 4 (which is usually expressed on stimulated T 
cells) used in vasculitis with positive results, mild efficacy [96], mild GC-sparing 
effect [5] There is an ongoing Phase III clinical trial [93].
Blocking IL-12/23 by binding to their common p40 subunit, with another 
monoclonal antibody ustekinumab has according to one report a positive influence 
in relapsing GCA [97]. Ustekinumab administered after rapid decrease in GS dose 
did not prevent disease relapse in one recent small study [98], it still has an open 
trial label for comparative multicenter study comparing GS alone treatment to GS 
and ustekinumab in refractory GCA [43].
Macrophages’ activation various pathways (mediated by IFN-ỿ, TNFα, CSF-2/
CSF-2R (CSF-2: colony-stimulating factor 2), IL 6/IL-6 receptor) [2] should be 
therapeutically targeted in GCA to prevent blood vessel destruction [54, 56] and the 
faulty vascular reparatory remodeling [2, 38, 54, 57, 62]. For instance, mavrilim-
umab is another agent under clinical trial for GCA treatment, targeting macrophage 
CSF-2/CSF-2R [43].
One of the most promising targets are Janus Kinase (JAK) inhibitors which are 
pursuing to block the signaling pathways of cytokines. JAKs are kinases that are 
involved in the signaling of different cytokines. The JAK inhibitors would possibly 
block different cytokines at the same time. It will be interesting to see whether block-
ing JAKs in GCA artery will block the signaling of both vascular inflammation (IL6-
mediated pathway) and vascular remodeling (IFNỿ-mediated pathway) at the same 
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time. This very interesting concept was first demonstrated by the Weyand research 
group, by blocking concomitantly vascular inflammation and vascular remodeling, 
with tofacitinib (an inhibitor of Jak1 and 3) as shown in ex vivo studies by Zhang 
et al. 2017 [36]. SELECT-GCA is an ongoing Phase III clinical trial investigating 
Upadacitinib, another JAK inhibitor for active GCA, at new onset or relapse [43, 93].
4.3.3 Future therapeutical strategies and developments
In terms of therapeutic strategy, the question to ask is which targeted therapy 
has more GS-saving effects, and also which of them reduces vascular dysfunction 
and vascular remodeling, which is still the “unmet need” in GCA treatment. For 
these purposes, we could target by blocking different molecules for instance, endo-
thelin 1, PDGF, mTor (rapamycin) [43]. TLR-induced activation of dendritic cells 
attracts and retain more dendritic cells and promote the activation of TH1 and TH17 
cells, one of the putative therapeutic development would be TLR blockage [5]. vWF 
and its crosstalk with LRP4/integrin αvβ3 axis could also constitute a future target 
for new therapeutics (monoclonal antibody against VWF to prevent pathological 
hyperplasia of the GCA arterial wall [58], or as possible future research perspec-
tive and therapy objective one could investigate could be using a small molecule 
to inhibit Weibel-Palade bodies secretion from arterial ECs [82, 99] and therefore 
control ECs mediators’ availability.
The impact of targeted GCA treatment on vascular inflammation and vascular 
remodeling, associated with vascular complications, needs to be further evaluated 
[22, 95] for more insight into the vascular inflammation and vascular repair unique 
features specific to GCA.
5. Discussion and conclusions
In this review study, we discussed several cellular and molecular pathogenetic 
mechanisms of vascular damage characteristic to GCA, that might occur during the 
progress of disease, especially during the active phase of the disease.
The paradigm in terms of GCA physiopathology is that inflammation starts 
in the adventitial layer with the activation of the vascular DCs which shifts the 
situation to the point where there are multiple types of immune cells recruited, 
proliferating, and differentiating in the vessel wall, causing together with inflamed 
vascular cells an erroneous repair of the arterial wall. It is unlikely that DCs are the 
one cells driving these processes, given the multitude of cell functions the arterial 
wall’s ECs play in complicated processes of vascular inflammation, hemostasis/
thrombosis, and vascular repair, resulting in a distinct GCA-specific vasculopathy 
most commonly term used in the field is GCA-related vascular remodeling. There 
are three ECs populations in GCA artery: arterial luminal ECs, vasa vasorum ECs 
and capillary ECs formed de novo in the intima and media layers (which showed be 
avascular in a normal arteries) of the diseased artery. These three types of ECs are 
activated in a sequential manner, probably their activation is subordinated to the 
invading immune cells, but not to all. For instance, vasa vasorum ECs are activated 
after vascular DCs are activated but ECs activation most probably precedes the 
activation of T cells. The invading cells must get in the vessel wall through the vasa 
vasorum. Activated ECs provide the means for invasion by mobilizing, preformed 
contents of storage granules WPBs. These secreted ECs mediators are released in 
a timely manner to fulfill proinflammatory, chemoattractant and neoangiogenic 
roles, or increased endothelial permeability functions.
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Biomarkers have the potential to detect the disease that is missed by TAB/imag-
ing. Several large multi-centers clinical trials being done recently [43, 71, 95, 96] 
led to the discovery of new potential biomarkers to monitor disease activity and 
relapses, which is a new critical development in the field. Some of the recently 
published data imply that testing several blood acute phase reactants can optimize 
earlier diagnosis and the ability to predict flares and complications [73, 93].
In addition, our study underlines the importance of the candidate targets for 
novel therapeutics. In the more severe complications of this disease-as blindness 
or stroke-the underlying GCA-related vascular damage does not respond to GS, as 
previously reported by several independent studies. A multistep treatment for GCA 
should be envisioned which involves first line: steroids, especially when people with 
GCA are particular ill; and secondly, efficient medication to control vascular dys-
function (for instance to lower proinflammatory cytokine levels, to lower the levels 
of circulating active vWF in parallel). From the variety of GCA treatments that 
are being investigating a few have the potential to improve outcomes and reduce 
the need for steroids. The availability of new drug tocilizumab was received with 
a lot of enthusiasm it is the only FDA approved drug specific for GCA treatment. 
Tocilizumab is effective to control GCA symptoms, allows rapid GS tapering, and 
persistent remission with a low dose GS after 6 mo followup, however after tocili-
zumab discontinuation the relapse-free survival (%) decreases, at least in some 
patients. Tocilizumab poses certain challenges for clinicians regarding biomarkers 
follow-up of patients, since tocilizumab is repressing both CRP and ESR; therefore, 
making careful anamnesis, physical examination, and clinical judgement even 
more important part of the disease assessment. 20 adverse events were considered 
directly related to drug; danger with tocilizumab administration was reported in 
the instance of infection in patients receiving tocilizumab [43, 93], with pneumonia 
and no CRP and ESR rise, [43] signifying that more careful assessing of the disease 
activity and infections in the patients treated with tocilizumab is required [43]. 
Further studies are needed to determine the optimal duration of treatment and 
maintaining of dosing and to further reduce the risk of relapse [93]. An important 
note to make is that molecular pathogenic pathways promoting GCA disease are 
changing with the disease progression under treatment [93]. This situation is fre-
quent in clinical practice and requires adequate follow-up and adapted therapeutic 
strategies [93].
Hopefully, future research will bring us closer to the goal of identifying new 
therapy for active and/or refractory GCA, which used in substitution or addition 
to steroids will provide tide control of the disease, addressing not only vascular 
inflammation but also vascular remodeling, skewed thrombotic propensity and 
luminal changes in GCA patients at the brink of having VL, or a stroke or other 
ischemic event at the initial onset of the arterial disease or in evolution.
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